Peter G. Traber

Internal Medicine

6620 Main St Fl 12
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.

Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity.

Journal: Oncoimmunology

Published: March 15, 2021

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.

Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.

Journal: Journal for immunotherapy of cancer

Published: March 08, 2021

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.

Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.

Journal: Gastroenterology

Published: April 12, 2019

Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

Galectin-3 is expressed in vascular smooth muscle cells and promotes pulmonary hypertension through changes in proliferation, apoptosis, and fibrosis.

Journal: American journal of physiology. Lung cellular and molecular physiology

Published: February 07, 2019

Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.

Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial.

Journal: PloS one

Published: May 21, 2018

Galectin-3 Promotes Vascular Remodeling and Contributes to Pulmonary Hypertension.

Galectin-3 Promotes Vascular Remodeling and Contributes to Pulmonary Hypertension.

Journal: American journal of respiratory and critical care medicine

Published: January 25, 2018

A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis.

A phase 2a, open-label pilot study of the galectin-3 inhibitor GR-MD-02 for the treatment of moderate-to-severe plaque psoriasis.

Journal: Journal of the American Academy of Dermatology

Published: May 02, 2017

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.

Journal: Alimentary pharmacology & therapeutics

Published: February 06, 2016

Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.

Binding of polysaccharides to human galectin-3 at a noncanonical site in its carbohydrate recognition domain.

Journal: Glycobiology

Published: December 10, 2015

Therapy of experimental NASH and fibrosis with galectin inhibitors.

Therapy of experimental NASH and fibrosis with galectin inhibitors.

Journal: PloS one

Published: September 09, 2013

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.

Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease.

Journal: PloS one

Published: May 31, 2013

Showing 1-11 of 11

Last Updated: 09/26/2026